laruparetigene zovaparvovec
AXP000261.1 · Viral vector gene therapy
- Platform
- AAV vector
- Targets
- RPGR
- Originator
- Applied Genetic Technologies Corporation
- Sponsor
- Beacon Therapeutics
Names
| Name | Type | Source |
|---|---|---|
| laruparetigene zovaparvovec | preferred name | curator |
| AGTC-501 | code | curator |
| laru-zova | synonym | curator |
Virus
- Role
- In vivo gene transfer
- Family
- Parvoviridae
- Virus
- adeno-associated virus
- Replication
- non replicating
- Transgenes
- RPGR
- Route
- subretinal
- Source
- evidence
Approvals
No regulatory approval recorded.
Clinical trials (3)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT07174726 | A Phase 2 Open-label Study to Evaluate the Safety of Laruparetigene Zovaparvovec Administered Bilaterally in Male Participants With X-Linked Retinitis Pigmentosa | Active not recruiting | Phase 2 | 2025-09-10 | 2029-12-31 | 10 | X-Linked Retinitis Pigmentosa (XLRP) |
| NCT04850118 | A Clinical Trial Evaluating the Safety and Efficacy of a Single Subretinal Injection of AGTC-501 in Participants With XLRP | Active not recruiting | Phase 2/3 | 2024-03-14 | 2026-06-30 | 85 | X-Linked Retinitis Pigmentosa |
| NCT06275620 | A Study Comparing Two Doses of AGTC-501 in Male Participants With X-linked Retinitis Pigmentosa Caused by RPGR Mutations (DAWN) | Enrolling by invitation | Phase 2 | 2023-11-14 | 2025-11 | 24 | X-Linked Retinitis Pigmentosa |
Unconfirmed matches (1)
Trials that mention one of the names in a weaker way (a code only in the title, a short or ambiguous name). Not counted above.
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions | Matched by |
|---|---|---|---|---|---|---|---|---|
| NCT06333249 | A Study Comparing Two Doses of AGTC-501 in Male Subjects With X-linked Retinitis Pigmentosa Caused by RPGR Mutations (SKYLINE) | Active not recruiting | Phase 2 | 2021-04-13 | 2023-04-11 | 14 | X-Linked Retinitis Pigmentosa | name in title: AGTC-501 |
Recent changes
No changes recorded in its trials yet.
Clinical papers
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 39643074 | Subretinal Gene Therapy Drug AGTC-501 for XLRP Phase 1/2 Multicenter Study (HORIZON): 24-Month Safety and Efficacy Results. | American journal of ophthalmology | 2025 | name in title: AGTC-501 |
| PMID 40146151 | Addressing Multiplicity in Retinal Sensitivity Analysis: An Alternative Approach to Assessing Gene Therapy Efficacy in Inherited Retinal Diseases. | Translational vision science & technology | 2025 | name in abstract: AGTC-501 |
| PMID 40547876 | Systematic Identification of Candidate Genes for Inherited Retinal Disease Gene Therapy Integrating Worldwide IRD Cohort and Single-Cell Analysis. | Journal of ophthalmology | 2025 | cited by trial NCT04850118 |
Other papers
Preclinical studies, reviews and other papers that name it.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 39941570 | Pre-Clinical and Clinical Advances in Gene Therapy of X-Linked Retinitis Pigmentosa: Hope on the Horizon. | Journal of clinical medicine | 2025 | name in abstract: AGTC-501 |
| PMID 31910043 | Toxicity and Efficacy Evaluation of an Adeno-Associated Virus Vector Expressing Codon-Optimized RPGR Delivered by Subretinal Injection in a Canine Model of X-linked Retinitis Pigmentosa. | Human gene therapy | 2020 | name in abstract: AGTC-501 |
| PMID 32414297 | Dose Range Finding Studies with Two RPGR Transgenes in a Canine Model of X-Linked Retinitis Pigmentosa Treated with Subretinal Gene Therapy. | Human gene therapy | 2020 | name in abstract: AGTC-501 |
| PMID 30280954 | Toxicology and Pharmacology of an AAV Vector Expressing Codon-Optimized RPGR in RPGR-Deficient Rd9 Mice. | Human gene therapy. Clinical development | 2018 | name in abstract: AGTC-501 |
Notes
Subretinal AAV gene therapy delivering RPGR for X-linked retinitis pigmentosa, in the phase 2/3 VISTA trial NCT04850118. The capsid is a tyrosine-mutant AAV2 in the sponsor's own naming (AAV2tYF), but no source read here states it, so `strain` is empty. AGTC became Beacon Therapeutics.
How to cite
laruparetigene zovaparvovec (AXP000261.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000261.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.